Literature DB >> 8383942

Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.

S Arai1, Y Gohara, A Akashi, K Kuwano, M Nishimoto, T Yano, K Oizumi, K Takeda, T Yamaguchi.   

Abstract

The efficacies of the new quinolones temafloxacin, ofloxacin, and ciprofloxacin were investigated against Mycoplasma pneumoniae in an experimental hamster pneumonia model. Hamsters were infected intratracheally with M. pneumoniae and sacrificed 18 h after the final medication, and their lungs were aseptically removed, homogenized, and cultured quantitatively. The efficacies of these drugs were determined by the CFU of M. pneumoniae in lungs. Temafloxacin and ofloxacin, but not ciprofloxacin, were active when the oral administration of 200 mg/kg of body weight per day (once per day) for 5 days was initiated 24 h after infection. Although no effect on the elimination of M. pneumoniae was observed after the administration of these drugs at 200 mg/kg/day at 5 days after infection, the continuous administration for 15 days of temafloxacin, but not ofloxacin or ciprofloxacin, significantly reduced viable M. pneumoniae in the lungs. These results suggest that temafloxacin and ofloxacin are effective in the acute phase of infection and, moreover, that temafloxacin is effective in the late stage of infection during which progressive lung alterations and continuous increases in mycoplasmal growth occurred. The peak levels of temafloxacin in sera and lungs after oral administration were similar to those of ofloxacin and higher than those of ciprofloxacin. The areas under the curve of temafloxacin in the lung tissue, however, were higher than those of ofloxacin and ciprofloxacin. On the basis of these results, temafloxacin and ofloxacin might be promising antimicrobial agents for the treatment of mycoplasmal infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383942      PMCID: PMC187654          DOI: 10.1128/AAC.37.2.287

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Antimycoplasmal activity of ofloxacin (DL-8280).

Authors:  Y Osada; H Ogawa
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

4.  Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.

Authors:  G H Cassell; K B Waites; M S Pate; K C Canupp; L B Duffy
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Sep-Oct       Impact factor: 2.803

5.  Parameters of Mycoplasma pneumoniae infection in Syrian hamsters.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; R Harasawa; S Razin
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

6.  Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.

Authors:  E Azoulay-Dupuis; J P Bedos; E Vallée; D J Hardy; R N Swanson; J J Pocidalo
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

7.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

8.  Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells.

Authors:  T Misu; S Arai; M Furukawa; Y Yamamoto; T Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

9.  In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors:  K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 10.  Pharmacokinetic disposition of quinolones in human body fluids and tissues.

Authors:  F Sörgel; U Jaehde; K Naber; U Stephan
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more
  9 in total

1.  In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

Authors:  M Takahata; M Shimakura; R Hori; K Kizawa; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.

Authors:  K Hamamoto; T Shimizu; N Fujimoto; Y Zhang; S Arai
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.

Authors:  Matthew E Griffith; James E Moon; Erica N Johnson; Kyra P Clark; Joshua S Hawley; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

4.  Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.

Authors:  M Kaku; K Ishida; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  Limited effects of temafloxacin compared with ciprofloxacin on T-lymphocyte function.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.

Authors:  Y Gohara; S Arai; A Akashi; K Kuwano; C C Tseng; S Matsubara; M Matumoto; T Furudera
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study.

Authors:  Yu-Dong Yin; Rui Wang; Chao Zhuo; Hui Wang; Ming-Gui Wang; Can-Mao Xie; Dan-Yang She; Xin Yuan; Ren-Tao Wang; Bin Cao; You-Ning Liu
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

9.  The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum.

Authors:  Nan Zhang; Xiaoyan Gu; Xiaomei Ye; Xun Wu; Bingxu Zhang; Longfei Zhang; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  Front Microbiol       Date:  2016-05-04       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.